Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Restructuring Charges

Discontinued — last reported Q2 '26

Restructuring Charges at other companies

Cardinal Health logo
Cardinal HealthCAH
$25M-10.7%
Cencora logo
CencoraCOR
$60.63M+45.1%
Organon logo
OrganonOGN
$31M-64.0%

Segments

By segment

See full
Affordable Medicines$0-100%
AvKARE$0—

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×—
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development39,01747,96477,40088,004
Intellectual property legal development expenses2,0872,0173,6293,784
Acquisition costs7,600—12,753—
Restructuring and other charges5541,0241,2041,595
Charges (credit) related to legal matters, net8,057(390)8,751(390)
Other operating income(1,298)—(8,239)(5,122)
Operating income129,769111,372271,541211,719
Other (expense) income:

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s restructuring charges?
Amneal Pharmaceuticals, Inc. (AMRX) reported restructuring charges of $554K in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s restructuring charges changed year-over-year?
Amneal Pharmaceuticals, Inc.'s restructuring charges decreased by 45.9% year-over-year, from $1.02M to $554K.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s restructuring charges?
Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s restructuring charges has grown at a 22.7% compound annual growth rate (CAGR), from $1.86M to $4.21M.
What does restructuring charges mean?
One-time costs from reorganizing operations, including employee severance, facility closure costs, contract termination fees, and asset relocation expenses.

Ask your AI about Amneal Pharmaceuticals, Inc.'s restructuring charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude